The pathogenesis of genetically complex granulomatous diseases, such as sarcoidosis and latent tuberculosis, remains largely unknown. With the recent advent of more powerful research tools, such as genome-wide expression platforms, comes the challenge of making sense of the enormous data sets so generated. This manuscript will provide demonstrations of how in-silico (computer) analysis of large research data sets can lead to novel discoveries in the field of granulomatous lung disease.
INTRODUCTION
Biological systems are infinitely complex in that their behavior is a manifestation of the net sum of dynamic interactions between the host and environment. The host and environment are codependent variables, wherein the complex biological system of the host is strongly influenced by genetic and epigenetic factors, which, in turn, are driven by evolutionary pressures imposed by the environment. For example, the evolutionary pressure of malaria on humans in sub-Saharan Africa has selected for human genetic traits that would interrupt the life cycle of the parasite, manifesting as thalassemias and sickle-cell disease [1] . Thus, accurate models of systems biology must account for the complex and dynamic relationships between host and environment, including individual host variability, such as the effects of genetics, age, sex, occupation, medications/drugs, nutrition, and so on.
Fortunately, even the most intricate biological systems, such as the human body, have achieved a homeostatic balance that is regulated by a relatively small subset of cells, such as photoreceptor cells in the eyes, antigen-sensing or regulatory immune cells, and molecules (e.g., receptors, enzymes, and transcription factors). Biological systems are further confined by fundamental 'laws of science', such as the laws of thermodynamics (energy) and quantum mechanics (probability), which significantly simplifies model predictions. Nonetheless, classical reductionist research models focused on the functions of a single molecule or specific cell type are rarely adequate for the accurate representation of complex biological systems.
The field of 'systems biology' has emerged as a new approach to scientific discovery that emerged to predict the behavior of living systems. Systems biology is founded upon the study of numerous interacting components of complex systems using mathematical equations to predict their behavior over time and in response to relevant experimental conditions [2] .
IN-SILICO MODELING TO INTERPRET COMPLEX 'OMICS DATA
In-silico or computer modeling refers to a recent shift from conventional 'reductionist biology' to an 'integrative biology' approach that considers how the components of complex biological systems engage with one another to produce a biological effect, such as the host immune response to a pathogen or malignant transformation of a cell caused by genetic variability or environmental exposures. The tools-of-the-trade include systems mathematics and computer simulations, and the goal is to produce 'in-silico organisms' that represent their in-vivo counterparts [3] . The components of an in-silico biological model can be highly variable, but typically include molecular (e.g., genomic, cell signaling), biochemical (e.g., enzymatic), or physiological data. Although the mathematics of in-silico modeling is often complex (i.e., beyond the scope of this manuscript), the equations are necessarily constrained by the limits of biological behavior (i.e., what is possible and what is not), allowing the mathematical equations to be simplified significantly. Using immune responses to environmental antigens in the context of granulomatous inflammation as an example, it is feasible to construct model constraints that effectively reduce the model components from millions of biological components (interactions among various immune cells, each of which has its own set of genes, enzymes, cytokines, chemokines, receptors, transcription factors, noncoding RNA, etc.) to produce a greatly simplified model that considers the most important determinants of granulomatous inflammation. In this regard, mathematical model creation is an iterative process whereby new input from conventional biochemical or genetic experiments (e.g., human, animal, or in-vitro cell experiments) informs the modification of in-silico models to more closely match the biological system, including phenotypic variations of the disease. Such models have great potential for accelerating biological research based upon their interpretive (mechanistic) and predictive capacities, provided rapidly, and at low cost.
To better appreciate the challenges of reducing complex biological data into a more simplified form, it is useful to consider how mathematical modeling interfaces with huge biological data sets that are generated from high-throughput 'omics research. Based upon the premise that changes in the relative expression of proteins, genes, and lipids are reflective of the biological processes that contribute to disease, demands for systems biology expertise have rapidly expanded. Recent innovations in the field of biological research provide for the simultaneous measurement of multiple parameters from a single sample. For instance, using mass spectroscopy technology, the relative expression of hundreds of proteins can be determined from less than a milligram of tissue. More remarkably, nanogram quantities of DNA or RNA can be amplified, identified (based upon conserved nucleotide sequence), and quantified (relative expression) to yield a readout consisting of tens of thousands of genes and millions of RNA transcripts. The cumulative data so generated from protein, gene, and transcript expression analyses are designated as the 'proteome', 'genome', and 'transcriptome', respectively. The rapid evolution of proteomic, genomic, and other 'omics research techniques facilitated the generation of massive amounts of data, thereby creating challenges relating to the objective statistical analysis and subsequent interpretation of the data.
A thorough description of the complex algorithms applied to 'omics research is beyond the scope of this manuscript (the interested reader is encouraged to read the expert review by Joyce and Palsson [4] ); however, 'machine learning' techniques are among the most widely used approaches to address this problem [5 && ]. The algorithms used in machine learning include applications of graph theory and clustering, and can be applied in ways that incorporate existing information or ideas (supervised), that largely ignore preconceived ideas (unsupervised) or somewhere in between those two extremes (semisupervised). Machine learning techniques are valuable for identifying molecular patterns that correspond with disease pathogenesis and for detecting biomarkers that distinguish distinct disease phenotypes.
KEY POINTS
'Omics research platforms are capable of comprehensively identifying and quantifying numerous molecules in a biological sample, and in-silico models have been used to hypothesize how these molecules are likely to interact in the context of granulomatous lung disease.
In-silico models are only as good as the quality of the data that are used to develop them such that the performance of in-silico simulations requires validation using more conventional experimental approaches.
Well designed in-silico models promise to accelerate the pace while reducing the costs of research to advance our understanding and to improve the treatment of granulomatous lung diseases.
Among the earliest applications of systems biology to advance our understanding of granulomatous disease compared tissue gene expression in two distinct leprosy populations performed by Bleharski et al. [6] . Like sarcoidosis and tuberculosis (TB), leprosy presents as a clinical and immunological spectrum of disease. With the use of gene expression profiling, it was shown that gene expression correlates with and accurately classifies the clinical form of the disease. Genes belonging to the leukocyte immunoglobulin-like receptor (LIR) family, including LIR-7, were significantly upregulated in lesions of lepromatous patients suffering from the disseminated form of the infection. In functional studies, LIR-7 protein suppressed innate host defense mechanisms by shifting monocyte production from IL-12 toward IL-10 and by blocking antimicrobial activity triggered by Toll-like receptors. This study was the first to show that gene expression profiles may be useful in defining clinical forms of disease and providing novel insights into the regulation of immune responses in the context of granulomatous disorders [7] . The Bleharski study has inspired a number of subsequent studies that have further investigated the role of LIR-7 (a.k.a. LILRA2) in the pathogenesis of altered immunity in the context of infectious diseases [7, 8] .
Gene expression profiling has since been applied to study sarcoidosis disease pathogenesis using a systems biology approach. Crouser et al. compared lung tissue gene expression in sarcoidosis patients with disease-free controls of sarcoidosis using an unsupervised approach. Namely, using a well curated database representing the known functions of the gene product (e.g., transcription factor, enzyme, receptor, etc.) and considering the known interactions among the gene products (e.g., genes known to be regulated by specific transcription factors and receptors known to activate signaling pathways), an unbiased mathematical approach (i.e., having no a priori hypothesis as to how the genes interact) was employed to statistically determine the molecular processes, represented as gene 'networks', that differentiate sarcoidosis lung disease from normal lung disease. Based upon a statistical analysis that is roughly based upon the number of differentially expressed genes conforming to each gene network so identified, a molecular pathway that is regulated by the transcription factor signal transducer and activator of transcription 1 (STAT1) emerged as being statistically most probable (i.e., least likely to be explained by 'chance'). Furthermore, the two most highly expressed transcripts, MMP12 and ADAMDEC1, were included in this network [9] , but were not previously incriminated in the pathogenesis of sarcoidosis. Molecules of this class (metalloproteinases) are integral to the function of cells participating in granulomatous inflammation [10] , and it is interesting to note that the expression of ADAMDEC1 was the most prominent in cells located adjacent to the stroma, presumably immature antigen-producing cells [11] , whereas MMP12 (encoding a macrophage elastase enzyme) gene expression was highest in macrophages located within the granulomas. Gene and protein expressions of MMP12 and ADAMDEC1 were significantly higher in BAL samples from patients with clinically active sarcoidosis compared with those with inactive disease [9] , further supporting the likelihood that these molecules are integral to sarcoidosis pathogenesis. Subsequent investigations have shown that STAT1-regulated genes are highly expressed in extrapulmonary sarcoidosis tissues, leading the investigators to hypothesize that STAT1 may be a therapeutic target [12] . Thus, the 'machine learning' or computer-generated interpretation of large disease-specific 'omics data can be used to generate new hypotheses relating to disease mechanisms and treatments.
Differentiation of sarcoidosis from infectious lung diseases is a critical diagnostic consideration, given that the treatments typically administered for sarcoidosis (immune suppressants) are dramatically different (i.e., antibiotics for infections). The utility of genomic approaches for distinguishing sarcoidosis from infections has been challenged by recent publications showing minimal discernable differences between the two clinical conditions in terms of the signal derived from blood cells [13] . Yet unpublished data comparing gene expression of lung tissue from sarcoidosis patients (the same cohort described above) with lung tissue from patients with confirmed granulomatous infections (i.e., histologically and/or tissue cultures) showed patterns that were similar in many respects ( Fig. 1a ). However, two molecular pathways distinguished sarcoidosis from granulomatous infection in the lungs, and these pathways have implications for distinct disease mechanisms. Sarcoidosis was associated with higher expression of a specific major histocompatibility complex (MHC) class II complex, HLA-DRB1 (Fig. 1b) , a molecule well known to influence the pathogenesis of sarcoidosis, presumably through engagement of as yet unidentified environmental antigens [14, 15] . Furthermore, this pathway was predicted to be regulated to some degree by transcription factors encoded by PAX3, which has recently been incriminated in the pathogenesis of chronic obstructive pulmonary disease using a similar gene expression analysis platform [16] , and SIX1, which is thought to be instrumental during lung development [17] . Fungal infection was Gene expression was compared in lung tissue derived from sarcoidosis (n ¼ 6), infectious granulomatous disease (n ¼ 6; four atypical mycobacterium, two histoplasmosis), and disease-free controls (n ¼ 6) using the Affymetrix Human U133 Plus 2.0 gene array platform (Thermo Fisher Scientific Inc., Santa Clara, California, USA) using fold difference of more than 2, P less than 0.005, and false discovery rate of 3% as the criterion. Differentially expressed genes were then analyzed by Ingenuity Pathway Analysis [Ingenuity Systems (Qiagen Silicon Valley, Redwood City, California, USA)]. (a) Principal component analysis shows similar gene expression profiles in sarcoidosis (green) and infection (blue), which were distinct from controls (red). (b) Expression of a gene network that is predicted to be regulated by transcription factors PAX3 and SIX1 were higher (darker shades of red ¼ higher expression) in sarcoidosis compared with infection.
In-silico granuloma model review distinguished from sarcoidosis by higher expression of transcripts regulated by the 'B-cell complex' (Fig. 1c ), which has implications for B-cell development and maturation [18] , and B-cell antigen presentation to CD4 þ T cells via MHC class II receptors [19] .
IN-SILICO EPIGENETICS MODELS AND THE 'INTERACTOME'
The vast majority of the human genome is classified as 'noncoding' in that DNA does not encode a protein, tRNA, or other functional molecule, and for many years the noncoding DNA was considered to be useless. This concept has dramatically changed over the past several decades during which a number of functional small RNA transcripts have been discovered to arise from noncoding DNA, the function of which is to (in most cases) suppress the translation of mRNA by binding to complementary sequences in the 3 0 untranslated region, thereby negatively regulating mRNA translation [20 & ]. The most studied of the noncoding RNA are 'microRNA' (miRNA), so called because they are only 21-25 nucleotides in length. The suppression of mRNA is targeted to some degree in that each miRNA has different affinity for each mRNA, and in most situations the net expression of any given mRNA is regulated by several miRNAs simultaneously [20 & ]. Computer models have been developed to mathematically predict the most likely mRNA targets of any set of miRNA provided, which has implications for gene transcription [21] . Indeed, miRNA is used experimentally to suppress mRNA transcription.
Suppression of gene expression downstream of mRNA gene expression, such as is regulated by miRNA, is referred to as 'epigenetic' gene regulation. Epigenetics explains phenotypic variation among people with nearly identical genetics (e.g., siblings) and can be influenced by environmental factors, such as smoking, stress, or diet. Epigenetic factors are known to contribute to cancer risk [22] and to chronic inflammatory conditions, including inflammation in the context of granulomatous lung infections [23] .
The first attempt to interpret the epigenome in sarcoidosis was recently performed in my laboratory and provides interesting insights into the potential importance of miRNA in this disease. MiRNA array technology was used to quantify hundreds of known miRNAs in peripheral blood mononuclear cells from patients with active sarcoidosis compared with disease-free volunteers. There were dramatic differences in miRNA expression in these groups, and a subset of the highly differentially expressed miRNA was further validated in other sarcoidosis tissues (lung and lymph nodes). These 'highly expressed in sarcoidosis' miRNAs were then analyzed using online access to computer programs with the ability to predict mRNA targets of the miRNA in the data set (i.e., common mRNA targets of all miRNAs in the sample). The results of these investigations were very interesting in that the predicted miRNA targets were predicted to suppress TGFb and Winglessrelated integration site signaling pathways that regulate Th2 immune responses [24] . Presumably, these epigenetic mechanisms favor polarization away from Th2 immune responses toward the typical Th1 immune response that is characteristic of sarcoidosis and other granulomatous disorders.
Another variation on this theme, which requires yet another level of computer model complexity, is to model the interaction between highly expressed genes (mRNA) with highly expressed miRNA in the same biological sample. This type of analysis falls into the category of an 'interactome', wherein the sum of multiple molecular interactions, reflected by two or more 'omics platforms, are considered in the context of a clinical phenotype (e.g., disease). An example of the predicted interactions between differentially expressed genes and differentially expressed miRNA is shown in Fig. 2 . It is interesting to note that these molecular interactions represent many of the known stages of granuloma formation, including antigen presentation, T-cell and macrophage activation, and, as previously shown in human pulmonary sarcoidosis genomic studies, STAT1 signaling [9, 12] . Moreover, the pathway is predicted to regulate the production of cytokines (TNFa and IFNg) and other by-products of activated immune cells (neopterin) that are differentially expressed in the lungs of patients with pulmonary sarcoidosis [25] .
DYNAMIC MATH MODELS AS AN EXPERIMENTAL PLATFORM FOR GRANULOMATOUS DISEASE RESEARCH
In-silico models applied to human data, such as discussed previously, generally reflect a snapshot image of the disease. The static nature of such models is a major research limitation in that the evolution of granulomas is a dynamic process, including initiation, accumulation, maintenance, and resolution phases, which are altered in the context of human diseases such as sarcoidosis. In lieu of animal models that accurately model sustained pulmonary and systemic granuloma formation in human sarcoidosis or latent Mycobacterium tuberculosis infection, mathematical models of granulomatous disease may provide a practical alternative.
As with 'omics models that are based upon well curated knowledge platforms, math models rely upon accurate characterization of established molecular and cellular interactions represented by an interactive molecular network. The interaction of each network component with others is characterized as reinforcing or suppressing of other components based upon peer-reviewed scientific evidence. Each component of the model network is then represented by complex differential equations to account for all known interactions (e.g., activation, inhibition, degradation, and proliferation) with other components of the network (e.g., CD4 þ T-cell activity is promoted by antigenpresenting cells and is suppressed by regulatory T cells), which are solved simultaneously and reevaluated over time to determine how the components of the network change over time. During the construction of such mathematical models, it often becomes apparent that some model components are more influential than others in terms of changing the final configuration (steady state) that is achieved when all of the equations are solved on the computer. These sensitive system components most often possess the capacity to amplify a biological signal (e.g., cell receptor, transcription factor, enzyme and cytokine) and, as such, become molecules of interest for future mechanistic or therapeutic research [26] .
Mathematical models are only as good as the model assumptions, and, as such, it is best to generate the models from actual human data. An example of how mathematical modeling can be applied to granulomatous disorders is provided by a recent study by Hao et al. [27 && ]. Based upon the known interactions of critical granuloma components (immune cells, chemokines, and cytokines) ( Fig. 3a) and related quantitative data derived from human sarcoidosis tissues, it is shown that the mathematical model closely replicates the molecular profile of human pulmonary sarcoidosis (Fig. 3b) . Moreover, perturbations of the model equating with the effects of various 'treatments' or 'genetic variation' (e.g., anti-TNFa drugs or the effects of genetic or epigenetic factors that influence TNFa activity) are shown to equate with a change in steady-state conditions that influence the predicted burden of granulomatous disease (Fig. 3c) [27 && ]. As is the case
In-silico granuloma model review Crouser with computer models previously described, it is important to emphasize that computer simulations require validation using more conventional research approaches (e.g., randomized controlled clinical trials) and may require modification as new information becomes available (e.g., newly discovered molecular interactions).
The next frontier of granulomatous disease research has to further consider the dynamic interaction of the host with the environment, as relates to the course of disease. In this regard, new evidence is emerging to support the notion that occupational exposures can adversely influence the clinical course of sarcoidosis [28] , and there is strong evidence showing that the interaction between host immune components and infections, such as TB, are associated with dynamic biological adjustments by both the host and pathogen that dictate disease phenotypes, ranging from complete eradication of infection to latent infection or fulminant infection. As such, the mathematical representation of the host and pathogen become interdependent and are critical when considering disease mechanisms or potential treatments. A very recent attempt to create an in-silico model representing the complexity of host-pathogen interactions in the context of human TB was reported by Hao et al. [29] . The selection of host and pathogen model components, including their functions and the expected magnitude of the effect (represented by a rate constant), were derived from the available literature and with guidance from an established expert in the field of TB host-pathogen immunology. The results of the model dynamics were expressed in terms of the 'total bacterial load', reflecting the degree to which the host immune response controlled mycobacterial growth over time. The results were interesting in that proinflammatory mediators, such as TNFa and IFNb, often presumed to be the most important variables regulating the growth of mycobacteria in humans, were not deemed to be most critical for suppressing TB growth. Instead, the transition from a M1 to M2 macrophage phenotype was shown to depend upon IL-10, a potent inhibitor of proinflammatory pathways in the context of granulomatous infections [30, 31] . Furthermore, suppression of IL-10 activity (e.g., using anti-IL-10 antibody treatment) was predicted to delay the M1 (favoring miRNA-KEY FIGURE 2. Predicted interactions between genes and microRNA in pulmonary sarcoidosis. Genes that were differentially expressed in lung tissues of patients with pulmonary sarcoidosis compared with controls (as described in Fig. 1 ) are depicted according to the function of their protein products. The predicted targets of differentially expressed microRNA transcripts, which were identified in pulmonary sarcoidosis in a previously published report [23] , were then analyzed using curated online microRNA target prediction resources [microRNA.org (Memorial Sloan-Kettering Cancer Center, New York, New York, USA), targetscan.org (Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA)]. The predicted interactions among gene products are represented by black arrows, and the predicted interactions of specific microRNA with specific genes are represented by color-coded triangles. The sum total of these interactions is designated the 'interactome'.
inflammation) to M2 (favoring repair) transition, thereby decreasing the bacterial burden, in a dosedependent fashion. Additional information about the adaptive responses of TB pathogens to IL-10 treatment is required to validate these results and to potentially identify new mechanisms by which the pathogens are capable of escaping the host immune response. New discoveries of this sort would be incorporated into a revised version of the in-silico model. And so goes, until the model is shown to sufficiently model the human condition in terms of predicting the superimposed effects of human variability (e.g., genetic and environmental factors) or model perturbations (e.g., proposed treatments).
CONCLUSION
With the advent of 'omics research and a shift toward attempts to comprehend complex molecular interactions, or systems biology, mathematical or in-silico modeling has emerged as an essential research tool. Just as computers have led to innovations in the fields of communication, aerospace, automobile performance, and almost every other technology-dependent field, the next generation of health-science researchers will increasingly rely on mathematical and computer models to understand the biological complexities of human health and disease. In the future, mathematical and computer models may replace much of the time-consuming and expensive preclinical research that is conducted on animals in the laboratory setting or in humans leading to more rapid progress toward understanding and treating human diseases. In the context of sarcoidosis, the anticipated expansion of knowledge relating to the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) study, including genomic information from diseased humans and environmental factors influencing their immune environment (the microbiome) [32] , will provide the substrate for more advanced in-silico models and related insights into dynamic disease mechanisms and novel treatments. The success of the GRADS program will accentuate the transition from reliance on conventional, hypothesis-driven research toward discoveries based upon systems biology research platforms and related computer models. 
